» Articles » PMID: 37304577

Immunosuppressive Dead Cell As Lung-targeting Vehicle and Cytokine Absorption Material for Cytokine Storm Attenuation of Pneumonia

Overview
Journal Mater Today Bio
Date 2023 Jun 12
PMID 37304577
Authors
Affiliations
Soon will be listed here.
Abstract

Effectively controlling cytokine storm is important to reduce the mortality of severe pneumonia. In this work a bio-functional dead cell was engineered by one-time quick shock of live immune cells in liquid nitrogen, and the obtained immunosuppressive dead cell could server as both lung-targeting vehicle and cytokine absorption material. After loading the anti-inflammatory drugs of dexamethasone (DEX) and baicalin (BAI), the drug-loaded dead cell (DEX&BAI/Dead cell) could first passively target to the lung after intravenous administration and quickly release the drugs under high shearing stress of pulmonary capillaries, realizing drug enrichment in the lung. Then, the immunosuppressive dead cell acted as the camouflage of normal immune cells with various cytokine receptors exposing on their surface, to "capture" the cytokines and further reduce the state of inflammation. With above formulation design, a synergic anti-inflammatory effect between drugs and carrier could be achieved. In a lipopolysaccharide-induced pneumonia mice model, this system could calm down the cytokine storm with high efficacy and elongate the survival of mice.

Citing Articles

A cryo-shocked M2 macrophages based treatment strategy promoting repair of spinal cord injury via immunomodulation and axonal regeneration effects.

Lu E, Zhou K, Miao J, Zhu Y, Tang J, Du S J Nanobiotechnology. 2025; 23(1):8.

PMID: 39757205 PMC: 11702283. DOI: 10.1186/s12951-024-03018-x.

References
1.
Dai J, Chen Z, Wang S, Xia F, Lou X . Erythrocyte membrane-camouflaged nanoparticles as effective and biocompatible platform: Either autologous or allogeneic erythrocyte-derived. Mater Today Bio. 2022; 15:100279. PMC: 9119842. DOI: 10.1016/j.mtbio.2022.100279. View

2.
Fang R, Gao W, Zhang L . Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Rev Clin Oncol. 2022; 20(1):33-48. DOI: 10.1038/s41571-022-00699-x. View

3.
Anselmo A, Gupta V, Zern B, Pan D, Zakrewsky M, Muzykantov V . Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano. 2013; 7(12):11129-37. PMC: 4128963. DOI: 10.1021/nn404853z. View

4.
Zhang N, Wang Z, Zhao Y . Selective inhibition of Tumor necrosis factor receptor-1 (TNFR1) for the treatment of autoimmune diseases. Cytokine Growth Factor Rev. 2020; 55:80-85. DOI: 10.1016/j.cytogfr.2020.03.002. View

5.
Wei X, Ran D, Campeau A, Xiao C, Zhou J, Dehaini D . Multiantigenic Nanotoxoids for Antivirulence Vaccination against Antibiotic-Resistant Gram-Negative Bacteria. Nano Lett. 2019; 19(7):4760-4769. PMC: 6711367. DOI: 10.1021/acs.nanolett.9b01844. View